Prevention of cardiovascular disease in adult recipients of kidney transplants

Although advances in immunosuppression, tissue typing, surgery, and medical management have made transplantation a routine and preferred treatment for patients with irreversible renal failure, successful transplant recipients have a greatly increased risk of premature mortality because of cardiovasc...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2011, Vol.378 (9800), p.1419-1427
Main Authors: Jardine, Alan G, Prof, Gaston, Robert S, Prof, Fellstrom, Bengt C, Prof, Holdaas, Hallvard, MD
Format: Article
Language:English
Subjects:
Adult
adults
Biological and medical sciences
Cardiovascular diseases
Cardiovascular Diseases - prevention & control
diabetes
diabetes mellitus
Diabetes Mellitus - etiology
disease control
drugs
Dyslipidemias - drug therapy
Dyslipidemias - etiology
General aspects
Historical account
Humans
hyperlipidemia
hypertension
Hypertension - drug therapy
Hypertension - etiology
Immunosuppressive Agents - adverse effects
Internal Medicine
kidney transplant
kidney transplantation
Kidney Transplantation - adverse effects
Medical sciences
Mortality
natural history
patients
prevention
Prevention and actions
Public health. Hygiene
Public health. Hygiene-occupational medicine
renal failure
risk
Risk Factors
surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although advances in immunosuppression, tissue typing, surgery, and medical management have made transplantation a routine and preferred treatment for patients with irreversible renal failure, successful transplant recipients have a greatly increased risk of premature mortality because of cardiovascular disease and malignancy compared with the general population. Conventional cardiovascular risk factors such as hyperlipidaemia, hypertension, and diabetes are common in transplant recipients, partly because of the effects of immunosuppressive drugs, and are associated with adverse outcomes. However, the natural history of cardiovascular disease in such recipients differs from that in the general population, and only statin therapy has been studied in a large-scale interventional trial. Thus, the management of this disease and the balance between management of conventional risk factors and modification of immunosuppression is complex.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(11)61334-2